Recursion Pharmaceuticals, Inc.
RXRX
$3.39
-$0.03-0.88%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 39.56% | -69.29% | -76.23% | -121.60% | -92.38% |
| Total Depreciation and Amortization | 50.40% | 192.35% | 165.93% | 162.04% | 71.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -40.10% | 68.94% | 166.51% | 214.38% | 135.17% |
| Change in Net Operating Assets | 494.35% | -9,860.61% | 579.32% | 83.95% | 75.96% |
| Cash from Operations | 60.09% | -98.16% | 7.06% | -28.99% | -55.82% |
| Capital Expenditure | 4.16% | 94.67% | -166.50% | 72.46% | 37.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 390,387.32% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -- | 11.40% | -- | 0.00% |
| Cash from Investing | -100.45% | 44.13% | -38.88% | -9.27% | 11,171.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.14% | 7.00% | -7,915.38% | -7,773.08% | -202.74% |
| Issuance of Common Stock | 953.16% | 1,251.90% | -60.96% | 205.78% | -84.34% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,140.77% | 1,426.79% | -62.88% | 191.62% | -86.81% |
| Foreign Exchange rate Adjustments | 160.11% | 363.77% | 7,943.22% | 2,306.85% | -2,900.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -48.10% | 384.09% | -86.02% | 1.48% | 3,863.80% |